A recent study in JAMA Dermatology evaluated drug survival rates in pediatric atopic dermatitis, finding that dupilumab demonstrated the highest 1-year survival rate of 84.1% among patients. The study offers valuable insights into the long-term effectiveness and safety of systemic therapies in pediatric patients with atopic dermatitis.
A recent study reveals that pregnant patients with hidradenitis suppurativa (HS) face significantly higher risks of pregnancy complications and adverse maternal and offspring outcomes, including gestational diabetes and hypertensive disorders.
With skin pigmentation influencing drug binding and potentially altering therapeutic outcomes, understanding melanin's role in pharmacokinetics is key to advancing equitable treatments.
Seventy percent of infants treated with once-weekly pulsed dye laser therapy for port-wine birthmarks achieved near-total or total clearance within just 2 months, as reported in a recent study published in JAMA Dermatology.
In a phase 3 trial, 67% of children treated with omalizumab tolerated 600 mg of peanut protein, a dramatic increase over just 7% with placebo, highlighting omalizumab’s potential in managing pediatric food allergies.
Two phase III clinical trials reveal promising results of once-daily roflumilast cream, 0.15%, in improving symptoms of atopic dermatitis within 4 weeks.
Eighty FCCs had properties that warrant further investigation for potential health concerns, such as carcinogenic, mutagenic, and reproductive toxicity.